Stock Price, News, Quote and Profile of ZURA BIO LTD(NASDAQ:ZURA) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ZURA BIO LTD

NASDAQ:ZURA (12/18/2024, 10:39:13 AM)

2.43

-0.08 (-3.19%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-26.61%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap158.65M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

Short Float %

Short Ratio

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies and are Phase II ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Company Info

ZURA BIO LTD

4225 Executive Square, Suite 600

La Jolla CALIFORNIA

P: 18582470520

Employees: 15

Website: https://zurabio.com/

ZURA News

8 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.